Why Is Myriad (MYGN) Up 8.7% Since Last Earnings Report?

Core Viewpoint - Myriad Genetics reported break-even earnings for Q3 2025, outperforming the Zacks Consensus Estimate of a loss of 1 cent per share, but total revenues decreased by 3.6% year-over-year to $205.7 million, slightly exceeding estimates [2][4]. Financial Performance - The company reported break-even earnings in Q3 2025 compared to earnings of 6 cents per share in the same quarter last year [2]. - GAAP net loss was 29 cents per share in Q3 2025, compared to a loss of 24 cents in the prior-year quarter [3]. - Total revenues for Q3 2025 were $205.7 million, a decrease of 3.6% year-over-year, but surpassed the Zacks Consensus Estimate by 0.24% [4]. Future Guidance - For 2025, Myriad forecasts revenues between $818 million and $828 million, with the Zacks Consensus Estimate currently at $821.9 million [5]. - Adjusted earnings per share are expected to range from a loss of 2 cents to earnings of 2 cents, with the consensus estimate at 1 cent for 2025 [5]. Estimate Revisions - Since the earnings release, there has been a downward trend in fresh estimates, with the consensus estimate shifting down by 7.89% [6]. - The overall direction and magnitude of estimate revisions have resulted in a Zacks Rank 3 (Hold) for Myriad, indicating an expectation of in-line returns in the coming months [8]. Industry Comparison - Myriad is part of the Zacks Medical - Biomedical and Genetics industry, where Biogen Inc. has gained 20.7% over the past month [9]. - Biogen reported revenues of $2.53 billion for the last quarter, reflecting a year-over-year change of +2.8%, with EPS of $4.81 compared to $4.08 a year ago [10].